SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending amid debates over its valuation following earnings, with community members pointing to its high P/E ratio while others defend its growth potential and strategic positioning in AI. Discussions also involve commentary from CEO Alex Karp and contrasting opinions on the stock's future, including Michael Burry's short position. Overall, the conversation reflects uncertainty about whether Palantir's current market price aligns with its long-term prospects.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending due to recent trial results for its PMO therapies, which, while showing positive trends, did not meet statistical significance, leading to community concerns about potential revenue impact. Despite this, discussions focus on the potential for label expansion of Elevidys, European sales, and possible mergers or acquisitions as long-term catalysts. Some traders also suggest shorts may have orchestrated the selloff.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels is trending due to a mixed reaction to earnings, with revenue doubling but EPS missing estimates, sparking debate about valuation and future guidance. Community members are discussing the potential for a short squeeze and government contracts, while also weighing the impact of a possible easing of rare earth export restrictions by China. Bullish sentiment remains strong among some investors who view Energy Fuels as a key player in the uranium and rare earth sectors, essential for energy independence and AI infrastructure.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending as investors discuss the potential impact of earnings results and a possible collaboration with Novo Nordisk. Community members are weighing the company's growth prospects amid concerns about profitability and regulatory pressures. Discussions also focus on potential short squeezes and the influence of institutional investors.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta (META) is trending amid investor concern over heavy AI spending and its potential impact on near-term profitability, leading to a sell-off from recent highs. Community discussions revolve around identifying a bottom and whether the stock is oversold, with some viewing the dip as a buying opportunity due to Meta's strong fundamentals and long-term potential in AI and VR.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is trending as its robotaxi fleet, Apollo Go, matches Waymo's pace with weekly ride volumes crossing 250K, sparking excitement around its autonomous vehicle leadership. Community members are also discussing catalysts from upcoming earnings and AI advancements, with some eyeing price targets. The stock's multi-year accumulation and perceived undervaluation as a Chinese stock are also driving interest.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The "crow with knife" meme coin, $CAW, is gaining attention, with community members emphasizing its multichain presence across $SOL, $ETH, $CRO, and BASE. Discussions highlight its fully circulated supply, deflationary mechanisms, strong community, and organic growth. The community is actively using the catchphrase "caw caw" and mentioning partnerships.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure ($QURE) is trending due to a significant FDA update on its Huntington's disease gene therapy, AMT-130, with community chatter focusing on the agency's changed stance. The stock experienced a sharp decline, and discussions revolve around the potential impact on the company's future, comparisons to similar situations in the biotech sector, and speculation about a possible rebound or acquisition.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending due to anticipation surrounding the Phase 3 HOPE-3 trial data release for its DMD treatment, deramiocel, expected in mid-November. Community discussions focus on the potential for positive results, mirroring earlier trial success, and what this could mean for FDA approval and market value. The recent failure of a Sarepta DMD trial is adding extra attention as investors look for alternative therapies.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending amid community discussions around upcoming token unlocks and their potential impact, with some expressing concerns about dilution while others remain bullish. The community is also actively debating Zebec's partnerships, super app, and overall utility. Sentiment is mixed, with some users calling out perceived scams, and others noting its payment infrastructure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues

RDY posts a Q2 earnings and revenue beat as global generics drive growth, while new launches and biosimilar advances shape its pipeline.

Strength Seen in Cartesian Therapeutics, Inc. (RNAC): Can Its 8.2% Jump Turn into More Strength?

Cartesian Therapeutics, Inc. (RNAC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Wall Street Analysts See a 105.88% Upside in Alvotech (ALVO): Can the Stock Really Move This High?

The mean of analysts' price targets for Alvotech (ALVO) points to a 105.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Voyager Therapeutics (VYGR) Soars 11.6%: Is Further Upside Left in the Stock?

Voyager Therapeutics (VYGR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Here's How Alvotech is Expanding its Portfolio Beyond Immunology

ALVO accelerates growth with soaring revenues and new biosimilars in ophthalmology, oncology and neurology via global alliances.

Alvotech (ALVO) Surges 8.6%: Is This an Indication of Further Gains?

Alvotech (ALVO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?

ALVO's partnership-driven model fuels surging biosimilar revenues, while TEVA leans on scale but faces debt and competitive pressures.

Here's How ALVO's Commercial Partnerships Are Driving Top-line Growth

Alvotech's partnership-led strategy drives soaring biosimilar revenues, fresh approvals and a diversified pipeline across key therapies.

ALVO Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?

Alvotech trades near a 52-week low after a 38% drop in 2025, but soaring revenues and new biosimilar approvals highlight its growth path.

Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus

KOD's Q2 loss widens as it ramps up clinical studies for three key eye disease treatments with pivotal data readouts planned.

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Róbert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

Alvotech

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Robinhood Markets Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

ALVO
Alvotech

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ALVO News

ALVOAlvotech